On July 17, 2020, Fairhaven Pharmaceuticals announced that it has been acquired by Liminal BioSciences. The acquisition includes Fairhaven’s preclinical research program of small molecule antagonists. Investigational therapies developed in the R&D program target a key chemoattractant and activator of eosinophils, which play a key role in inflammation-driven diseases.The acquisition continues Liminal’s strategic expansion to create a diverse portfolio of early stage R&D programs that complement its existing research.
Fairhaven Pharmaceuticals specializes in the development of small molecule, oral therapeutics for severe inflammatory conditions.
Liminal BioSciences is a clinical stage biopharmaceutical company specializing in discovering, developing and commercializing treatments for patients suffering from diseases related to fibrosis.
Osler, Hoskin & Harcourt LLP advised Fairhaven with a team consisting of David Jamieson, Kosta Starostin (Corporate), Martha Martindale (Financial Services), Colena Der (Taxation) and Amelia Miao (Securities).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Partner, Financial Services, Vancouver
Partner, Tax, Calgary
Partner, Corporate, Toronto
